Publications by authors named "Mark Levenberg"
Predicting Abrocitinib Efficacy at Week 12 Based on Clinical Response at Week 4: A Post Hoc Analysis of Four Randomized Studies in Moderate-to-Severe Atopic Dermatitis.
Dermatol Ther (Heidelb)
July 2024
Introduction: Early prediction of abrocitinib efficacy in atopic dermatitis (AD) could help identify candidates for an early dose increase. A predictive model determined week 12 efficacy based on week 4 responses in patients receiving abrocitinib 100 mg/day and assessed the effect of an abrocitinib dose increase on platelet counts.
Methods: Analysis included the phase 3 trials JADE MONO-1 (NCT03349060), MONO-2 (NCT03575871), COMPARE (NCT03720470), and TEEN (NCT03796676).
Article Synopsis
- The study investigated the effectiveness and safety of the medication abrocitinib for treating moderate-to-severe atopic dermatitis, focusing on different racial and ethnic groups.
- Data from three trials included self-reported race and ethnicity, as well as Fitzpatrick skin type, to compare responses to the treatment.
- Results showed that abrocitinib significantly improved skin conditions for all racial groups, with the most pronounced effects in White patients; however, Black patients had similar responses to both doses tested and reported more treatment-related side effects compared to Asian patients.
Costs and Treatment Patterns Among Patients with Atopic Dermatitis Using Advanced Therapies in the United States: Analysis of a Retrospective Claims Database.
Dermatol Ther (Heidelb)
August 2020
Introduction: For many, atopic dermatitis (AD) is not adequately controlled with topical regimens. This analysis examined treatment using advanced therapies and associated costs.
Methods: The IQVIA Health Plan Claims data set was analyzed.
The Challenge of Managing Atopic Dermatitis in the United States.
Am Health Drug Benefits
April 2019
Background: Atopic dermatitis is a chronic inflammatory skin disease that affects up to 13% of children and 10% of adults in the United States. Among patients and their families, atopic dermatitis has a considerable effect on quality of life and represents a substantial economic burden.
Objective: To describe the impact and challenges of atopic dermatitis and to provide nondermatologists in the healthcare community an enhanced understanding of atopic dermatitis to facilitate treatment and pharmacy benefit discussions.
Article Synopsis
- Atopic dermatitis (AD) is a common skin condition treated with topical corticosteroids (TCS) and calcineurin inhibitors (TCI), and crisaborole is a newly approved non-steroidal treatment for mild-to-moderate cases.
- The study assesses the real-world use and costs of TCS and TCI, as well as the budget impact of introducing crisaborole over two years for health insurance providers.
- Results showed that while the budget impact of crisaborole was relatively modest—a cost increase of $350,946 for TCS/TCI patients—its adoption could lower costs for patients using TCIs by about $22,871.